Surgical Pathology Clinics

Update on Flat and Papillary Urothelial Lesions

Genitourinary Pathology Society Consensus Recommendations
Published:October 12, 2022DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgical Pathology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Amin M.B.
        • Comperat E.
        • Epstein J.I.
        • et al.
        The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia.
        Adv Anat Pathol. 2021; 28: 179-195
        • JN E
        • G S
        • JI E.
        • et al.
        World Health Organization Classification fo Tumour. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs.
        Bd. 2004; 1
        • Humphrey P.A.
        • Moch H.
        • Cubilla A.L.
        • et al.
        The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours.
        Eur Urol. 2016; 70: 106-119
        • Obermann E.C.
        • Junker K.
        • Stoehr R.
        • et al.
        Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses.
        J Pathol. 2003; 199: 50-57
        • Epstein J.I.
        • Amin M.B.
        • Reuter V.R.
        • et al.
        The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.
        Am J Surg Pathol. 1998; 22: 1435-1448
        • Lopez-Beltran A.
        • Cheng L.
        • Andersson L.
        • et al.
        Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation.
        Virchows Arch. 2002; 440: 3-11
        • Lowenthal B.M.
        • Sahoo D.
        • Amin M.B.
        • et al.
        Urothelial Proliferation of Unknown Malignant Potential Involving the Bladder: Histopathologic Features and Risk of Progression in De Novo Cases and Cases With Prior Neoplasia.
        Arch Pathol Lab Med. 2020; 144: 853-862
        • Knüchel-Clarke R.
        • Gaisa N.T.
        [Preneoplastic lesions and precursors of urothelial cancer].
        Pathologe. 2016; 37: 33-39
        • van Oers J.M.M.
        • Adam C.
        • Denzinger S.
        • et al.
        Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder.
        Int J Cancer. 2006; 119: 1212-1215
        • Yee C.H.
        • Zheng Z.
        • Shuman L.
        • et al.
        Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS.
        Sci Rep. 2019; 9: 270
        • Babjuk M.
        • Burger M.
        • Capoun O.
        • et al.
        European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
        Eur Urol. 2022; 81: 75-94
        • McKenney J.K.
        • Gomez J.A.
        • Desai S.
        • et al.
        Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion.
        Am J Surg Pathol. 2001; 25: 356-362
        • Sangoi A.R.
        • Falzarano S.M.
        • Nicolas M.
        • et al.
        Carcinoma In Situ With Plasmacytoid Features: A Clinicopathologic Study of 23 Cases.
        Am J Surg Pathol. 2019; 43: 1638-1643
        • Neal D.J.
        • Amin M.B.
        • Smith S.C.
        CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia.
        Diagn Pathol. 2020; 15: 61
        • Khan M.S.
        • Thornhill J.A.
        • Gaffney E.
        • et al.
        Keratinising squamous metaplasia of the bladder: natural history and rationalization of management based on review of 54 years experience.
        Eur Urol. 2002; 42: 469-474
        • McKenney J.K.
        Precursor lesions of the urinary bladder.
        Histopathology. 2019; 74: 68-76
        • Pires-Luis A.S.
        • Martinek P.
        • Alaghehbandan R.
        • et al.
        Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
        Adv Anat Pathol. 2020; 27: 303-310
        • Ozkaptan O.
        • Cubuk A.
        • Dincer E.
        • et al.
        Adenocarcinoma in Orthotopic Neobladder 19 Years After Radical Cystoprostatectomy.
        J Coll Physicians Surg Pak. 2021; 30: 588-590
        • Armah H.B.
        • Krasinskas A.M.
        • Parwani A.V.
        Tubular adenoma with high-grade dysplasia in the ileal segment 34 years after augmentation ileocystoplasty: report of a first case.
        Diagn Pathol. 2007; 2: 29
        • Varma M.
        • Delahunt B.
        • van der Kwast T.
        Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question.
        Eur Urol. 2019; 76: 413-415
        • van der Kwast T.
        • Liedberg F.
        • Black P.C.
        • et al.
        a. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma.
        Eur Urol Focus. 2021; (S2405-4569(21)00096-101)
        • Sylvester R.J.
        • Rodríguez O.
        • Hernández V.
        • et al.
        a. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
        Eur Urol. 2021; 79: 480-488
        • Soukup V.
        • Čapoun O.
        • Cohen D.
        • et al.
        Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
        Eur Urol. 2017; 72: 801-813
        • Compérat E.
        • Larré S.
        • Roupret M.
        • et al.
        Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old.
        Virchows Arch. 2015; 466: 589-594
        • Compérat E.
        • Amin M.
        • Reuter V.
        Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol 2019;76:413-5: Two Decades of World Health Organisation/International Society of Urological Pathology Bladder Cancer Grading: Time to Reflect on Accomplishments and Plan Refinement in the Molecular Era, Not Regress to Readoption of a 45-year-old Classification.
        Eur Urol. 2019; 76: 416-417
        • Gofrit O.N.
        • Pizov G.
        • Shapiro A.
        • et al.
        Mixed high and low grade bladder tumors--are they clinically high or low grade?.
        J Urol. 2014; 191: 1693-1696
        • Cheng L.
        • Weaver A.L.
        • Leibovich B.C.
        • et al.
        Predicting the survival of bladder carcinoma patients treated with radical cystectomy.
        Cancer. 2000; 88: 2326-2332
        • Downes M.R.
        • Weening B.
        • van Rhijn B.W.G.
        • et al.
        Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
        Histopathology. 2017; 70: 281-289
        • Toll A.D.
        • Epstein J.I.
        Invasive low-grade papillary urothelial carcinoma: a clinicopathologic analysis of 41 cases.
        Am J Surg Pathol. 2012; 36: 1081-1086
        • Lawless M.
        • Gulati R.
        • Tretiakova M.
        Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression.
        Histopathology. 2017; 71: 406-414
        • Pan C.C.
        • Chang Y.H.
        • Chen K.K.
        • et al.
        Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder.
        J Clin Pathol. 2010; 63: 910-915
        • Compérat E.
        • Camparo P.
        • Haus R.
        • et al.
        Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms.
        Virchows Arch. 2007; 450: 419-424
        • Rebola J.
        • Aguiar P.
        • Blanca A.
        • et al.
        Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
        Virchows Arch. 2019; 475: 445-455
        • Bontoux C.
        • Rialland T.
        • Cussenot O.
        • et al.
        A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.
        Virchows Arch. 2021; 478: 637-645
        • Witjes J.A.
        • Bruins H.M.
        • Cathomas R.
        • et al.
        a. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.
        Eur Urol. 2020; 79: 82-104
        • Amin M.B.
        • Smith S.C.
        • Reuter V.E.
        • et al.
        Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer.
        Mod Pathol. 2015; 28: 612-630
        • Maxwell J.P.
        • Wang C.
        • Wiebe N.
        • et al.
        Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth.
        Diagn Pathol. 2015; 10: 3
        • Arslankoz S.
        • Kulaç İ.
        • Ertoy Baydar D.
        The Influence of Inverted Growth Pattern on Recurrence for Patients with Non-Invasive Low Grade Papillary Urothelial Carcinoma of Bladder.
        Balkan Med J. 2017; 34: 464-468
        • Almassi N.
        • Pietzak E.J.
        • Sarungbam J.
        • et al.
        Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities.
        J Pathol. 2020; 250: 464-465